Reviva Pharmaceuticals initiated with a Buy at Roth MKM

Roth MKM initiated coverage of Reviva Pharmaceuticals (RVPH) with a Buy rating and $7 price target The firm says its optimism is driven by brilaroxazine’s positive Phase 3 data demonstrating its impact on positive, negative and cognition symptoms in schizophrenia patients with an effect size greater than many antipsychotics. The “unequivocal” Phase 3 results underscore Reviva’s “de-risked clinical strategy,” the analyst tells investors in a research note.